المؤلفون: Baldassari LE; Division of Neuroimmunology, Department of Neurology, University of Utah, Imaging and Neurosciences Center, 729 Arapeen Drive, Salt Lake City, UT, 84108, USA., Rose JW; Division of Neuroimmunology, Department of Neurology, University of Utah, Imaging and Neurosciences Center, 729 Arapeen Drive, Salt Lake City, UT, 84108, USA. jrose@genetics.utah.edu.

المصدر: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics [Neurotherapeutics] 2017 Oct; Vol. 14 (4), pp. 842-858.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics Country of Publication: United States NLM ID: 101290381 Publication Model: Print Cited Medium: Internet ISSN: 1878-7479 (Electronic) Linking ISSN: 18787479 NLM ISO Abbreviation: Neurotherapeutics Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal, Humanized/*therapeutic use , Immunoglobulin G/*therapeutic use , Immunosuppressive Agents/*therapeutic use , Multiple Sclerosis/*drug therapy, Animals ; Antibodies, Monoclonal, Humanized/pharmacology ; Clinical Trials as Topic ; Daclizumab ; Humans ; Immunoglobulin G/pharmacology ; Immunosuppressive Agents/pharmacology ; Interleukin-2/immunology ; Multiple Sclerosis/immunology ; Receptors, Interleukin-2/immunology ; Treatment Outcome